Immunovant Inc. (IMVT)
Immunovant Statistics
Share Statistics
Immunovant has 169.86M shares outstanding. The number of shares has increased by 16.2% in one year.
Shares Outstanding | 169.86M |
Shares Change (YoY) | 16.2% |
Shares Change (QoQ) | 15.72% |
Owned by Institutions (%) | 54.54% |
Shares Floating | 68.32M |
Failed to Deliver (FTD) Shares | 2.18K |
FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 20.83M, so 12.26% of the outstanding shares have been sold short.
Short Interest | 20.83M |
Short % of Shares Out | 12.26% |
Short % of Float | 23.81% |
Short Ratio (days to cover) | 7.92 |
Valuation Ratios
The PE ratio is -16.83 and the forward PE ratio is -5.28. Immunovant's PEG ratio is -1.69.
PE Ratio | -16.83 |
Forward PE | -5.28 |
PS Ratio | 0 |
Forward PS | 3.5 |
PB Ratio | 7.07 |
P/FCF Ratio | -20.34 |
PEG Ratio | -1.69 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immunovant.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.7, with a Debt / Equity ratio of 0.
Current Ratio | 13.7 |
Quick Ratio | 13.7 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.25M |
Employee Count | 207 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 567K |
Effective Tax Rate | -0.22% |
Stock Price Statistics
The stock price has increased by -44.54% in the last 52 weeks. The beta is 0.81, so Immunovant's price volatility has been higher than the market average.
Beta | 0.81 |
52-Week Price Change | -44.54% |
50-Day Moving Average | 17.47 |
200-Day Moving Average | 25.01 |
Relative Strength Index (RSI) | 49.76 |
Average Volume (20 Days) | 1.81M |
Income Statement
Revenue | n/a |
Gross Profit | -231K |
Operating Income | -282.71M |
Net Income | -259.34M |
EBITDA | -269.98M |
EBIT | -270.21M |
Earnings Per Share (EPS) | -1.88 |
Balance Sheet
The company has 635.37M in cash and 138K in debt, giving a net cash position of 635.23M.
Cash & Cash Equivalents | 635.37M |
Total Debt | 138K |
Net Cash | 635.23M |
Retained Earnings | -825.68M |
Total Assets | 420.93M |
Working Capital | 344.23M |
Cash Flow
In the last 12 months, operating cash flow was -214.23M and capital expenditures -360K, giving a free cash flow of -214.59M.
Operating Cash Flow | -214.23M |
Capital Expenditures | -360K |
Free Cash Flow | -214.59M |
FCF Per Share | -1.55 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
IMVT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for IMVT is $45, which is 182% higher than the current price. The consensus rating is "Buy".
Price Target | $45 |
Price Target Difference | 182% |
Analyst Consensus | Buy |
Analyst Count | 10 |
Scores
Altman Z-Score | 16.78 |
Piotroski F-Score | 3 |